Lenvacent 10 mg (Capsule)
Unit Price: ৳ 1,750.00 (3 x 4: ৳ 21,000.00)
Strip Price: ৳ 7,000.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Lenvatinib mesylate |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Title and Categories
- Lenvacent Kinase Inhibitor
- Medicine
- Pharmaceutical Product
Indications
- Differentiated Thyroid Cancer
- Renal Cell Carcinoma
- Hepatocellular Carcinoma
- Endometrial Carcinoma
Pharmacology
- Inhibition of VEGF receptors
- Inhibition of FGF receptors
- Inhibition of PDGFR
- Antiproliferative activity in hepatocellular carcinoma cell lines
Absorption
Time to peak plasma concentration (Tmax) occurs from 1 to 4 hours post-dose
Distribution
In vitro binding to human plasma proteins ranged from 98% to 99%
Metabolism
Mainly through enzymatic and non-enzymatic processes
Elimination
Terminal elimination half-life of approximately 28 hours
Dosage
- Differentiated Thyroid Cancer: 24 mg orally once daily
- Renal Cell Carcinoma: 18 mg in combination with 5 mg Everolimus orally once daily
- Hepatocellular Carcinoma: 12 mg for patients ≥60 kg or 8 mg for patients <60 kg orally once daily
- Endometrial Carcinoma: 20 mg orally once daily in combination with Pembrolizumab 200 mg intravenously every 3 weeks
Administration
Capsules can be swallowed whole or dissolved in liquid
Interaction
Avoid coadministration with drugs that prolong the QT interval
Contraindications
Known hypersensitivity to Lenvatinib or any component of the formulation
Side Effects
- Hypertension
- Cardiac dysfunction
- Arterial thromboembolic events
- Hepatotoxicity
- Renal failure and impairment
- Proteinuria
- Diarrhea
- Fistula formation and gastrointestinal perforation
- QT Interval Prolongation
- Hypocalcemia
- Reversible posterior leukoencephalopathy syndrome
- Hemorrhagic events
- Impairment of thyroid stimulating hormone suppression/thyroid dysfunction
- Wound healing complications
Pregnancy & Lactation
- Potential embryo-fetal harm in pregnancy
- Effective contraception recommended during treatment
- Discontinue breastfeeding during treatment
Precautions & Warnings
- Hypertension monitoring and control
- Clinical monitoring for cardiac dysfunction
- Permanently discontinue after arterial thrombotic event
- Regular liver function monitoring
- Monitor renal function and proteinuria
- Prompt management of diarrhea
- Permanently discontinue for severe gastrointestinal complications
- Electrolyte abnormalities and QT interval monitoring
- Hypocalcemia management
- Neurologic symptoms monitoring
- Consider risk of hemorrhage
- Regular thyroid function monitoring
- Wound healing complications management
Use in Special Populations
- Dosage modifications for severe renal impairment
- Dosage modifications for severe hepatic impairment
- Pediatric use not established
Overdose Effects
High plasma protein binding, not expected to be dialyzable
Storage Conditions
Store below 30°C in a dry place, protect from light, keep out of the reach of children